LDN-214117
LDN-214117 is a selective small molecule inhibitor targeting the ALK2 kinase. It is utilized in research to investigate pathways involving bone morphogenetic proteins (BMPs), with applications in both cellular studies and animal models of fibrodysplasia ossificans progressiva (FOP) and other disorders.
Product Specifications
CAS Number
1627503-67-6
Product Name Alternative
ALK3, ALK2, ALK5, ALK1, bone morphogenetic proteins (BMPs), BMP6, BMP4, BMP2, diffuse intrinsic pontine glioma (DIPG), oral, fibrodysplasia ossificans progressiva (FOP), LDN 214117, LDN214117, LDN-214117, Transforming growth factor beta receptors, TGFβ, TGFbeta/Smad, TGF-β Receptor, TGF-β/Smad, TGF-b/Smad, TGFb, TGFbeta, TGF-beta, Smad, type I receptor kinases
Field of Research
Cardiovascular Research, Signal Transduction, Stem Cell & Developmental Biology
Purity
98.00% (May vary between batches)
Solubility
DMSO:4.2 mg/mL (10.01 mM) ; Ethanol:42 mg/mL (100.11 mM) ;10% DMSO+40% PEG300+5% Tween 80+45% Saline:1 mg/mL (2.38 mM)
Smiles
COc1cc (cc (OC) c1OC) -c1cc (cnc1C) -c1ccc (cc1) N1CCNCC1
Molecular Formula
C25H29N3O3
Molecular Weight
419.52
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
GTR15135083 1 Vial
Lentiviral human ZBTB17 shRNA (UAS) - Lentiviral human ZBTB17 shRNA (UAS, RFP) (25)
Sign In for Pricing
View Details 
